David R. Gandara, MD
Immunotherapy is rapidly altering the treatment landscape in non–small cell lung cancer (NSCLC), but many questions still remain, according to David R. Gandara, MD.
, Gandara, director of the Thoracic Oncology Program, professor at UC Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care in Lung Cancer, discussed the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.
OncLive: What is your reaction to the MYSTIC trial findings?
The results of the MYSTIC trial have been much anticipated. This is a phase III trial in advanced-stage NSCLC, randomizing patients to standard-of-care platinum chemotherapy versus either durvalumab (Imfinzi) alone or durvalumab plus tremelimumab, a CTLA-4 inhibitor.
... to read the full story